Convergence, collaboration and commercialization in cell and gene therapies

Featuring:

Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of Toronto

Audrey Greenberg, MBA, CEO & Founder, AG Capital Advisors

***

In this engaging episode of “Commercializing Living Therapies with CCRM,” we sit down with two leaders in the life sciences field: Molly Shoichet, a biomedical engineer and University Professor at the University of Toronto, and Audrey Greenberg, Founder and Managing Partner, AG Capital Advisors. Together, they bring a wealth of experience in commercializing scientific breakthroughs and building the infrastructure needed to bring transformative therapies to market.

Our guests explore some of the most exciting advances in cell and gene therapies today, including technologies with the potential to significantly impact patient outcomes. They also share insights into the companies they’re watching, the challenges and opportunities facing the field, and the evolving role of AI and automation in accelerating innovation. With practical advice on commercialization and reflections on public-private partnerships, this episode is a must-listen for anyone navigating the future of regenerative medicine.